Literature DB >> 15666359

Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.

Hitoshi Ishiguro1, Noboru Nakaigawa, Yasuhide Miyoshi, Kiyoshi Fujinami, Yoshinobu Kubota, Hiroji Uemura.   

Abstract

BACKGROUND: Advanced glycation end products (AGE) are produced with normal aging. Recently, some reports indicated that the interaction between AGE and the cognate receptor (RAGE) has a role in cancer dependent.
METHODS: We investigated RAGE and amphoterin mRNA expression in prostate cancer cell lines (DU145, PC-3, and LNCaP cells), hormone-refractory prostate cancer tissues, and paired untreated primary prostate cancer and normal prostate (including benign prostatic hypertrophy (BPH)) tissues using real-time quantitative PCR. Moreover, to confirm the AGE-RAGE interaction in prostate cancer, DU145 cells stimulated with AGE-bovine serum albumin (AGE-BSA) were examined by in vitro matrigel assay, cell viability assay, MTT assay, reverse transcription-polymerase chain reaction (RT-PCR), and Western blot.
RESULTS: DU145 cells, a hormone-independent prostate cancer cell line, showed the highest RAGE mRNA expression. Amphoterin mRNA was expressed in all three cell lines. In prostate tissues, untreated prostate cancer tissue and hormone-refractory prostate cancer tissue showed higher RAGE and amphoterin mRNA expression than normal prostate tissue. The AGE-RAGE interaction induced the invasion and growth in DU145 cells stimulated with AGE-BSA.
CONCLUSIONS: The AGE-RAGE interaction is important in prostate cancer development, and inhibition of this interaction has potential as a new molecular target for cancer therapy or prevention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15666359     DOI: 10.1002/pros.20219

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  73 in total

1.  HMGB1 promotes lymphangiogenesis of human lymphatic endothelial cells in vitro.

Authors:  Yuanyuan Qiu; Ying Chen; Xin Fu; Lei Zhang; Jing Tian; Quan Hao
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

2.  Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.

Authors:  Hiroji Uemura; Hisashi Hasumi; Takashi Kawahara; Shinpei Sugiura; Yasuhide Miyoshi; Noboru Nakaigawa; Jun-ichi Teranishi; Kazumi Noguchi; Hitoshi Ishiguro; Yoshinobu Kubota
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.402

3.  Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.

Authors:  Christian J Konopka; Marcin Woźniak; Jamila Hedhli; Anna Siekierzycka; Jarosław Skokowski; Rafał Pęksa; Marcin Matuszewski; Gnanasekar Munirathinam; Andre Kajdacsy-Balla; Iwona T Dobrucki; Leszek Kalinowski; Lawrence W Dobrucki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-12       Impact factor: 9.236

4.  AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation.

Authors:  Ji-Ming Bao; Min-Yi He; Ya-Wei Liu; Yong-Jie Lu; Ying-Qia Hong; Hai-Hua Luo; Zhong-Lu Ren; Shan-Chao Zhao; Yong Jiang
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

5.  Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an Advanced Glycation End Product) on Prostate Cancer: A Prospective Study.

Authors:  Shuman Yang; Susan M Pinney; Palash Mallick; Shuk-Mei Ho; Bruce Bracken; Tianying Wu
Journal:  Clin Genitourin Cancer       Date:  2015-04-18       Impact factor: 2.872

6.  Advanced glycation end product recognition by the receptor for AGEs.

Authors:  Jing Xue; Vivek Rai; David Singer; Stefan Chabierski; Jingjing Xie; Sergey Reverdatto; David S Burz; Ann Marie Schmidt; Ralf Hoffmann; Alexander Shekhtman
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

7.  GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation.

Authors:  Colleen S Curran; Michael D Evans; Paul J Bertics
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

8.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

9.  Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.

Authors:  Hye Won Chung; Sang-Guk Lee; Heejung Kim; Duck Jin Hong; Jae Bock Chung; David Stroncek; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2009-05-28       Impact factor: 5.531

10.  Detection of IgE, IgG, IgA and IgM antibodies against raw and processed food antigens.

Authors:  Aristo Vojdani
Journal:  Nutr Metab (Lond)       Date:  2009-05-12       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.